A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.

Abstract

Chimeric antigen receptor T (CAR-T) cells are a promising approach in hematopoietic malignancies. We evaluated the safety and efficacy of a combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma (R/RMM). Twenty-two R/RMM patients, with a median age of 56 years and a median number of previous therapies of 8, were included in the study. Both CAR-T cells infusion doses were 2.0 × 106/kg. The overall response rate (ORR) was 90.9%, with 12 patients (54.5%) achieving a strict complete response/complete response (sCR/CR). The 24-month overall survival (OS) rate was 56.6%, and the progression-free survival (PFS) rate was 48.7%. Cytokine release syndrome (CRS) of grades 1-2 occurred in 16 patients (72.7%) and of grade ≥3 in six patients (27.3%). Immune effector cell-associated neurotoxic syndrome (ICANS) of grades 1-2 occurred in three patients (13.6%). The combination therapy is potential in R/RMM patients.Trial registration: The patients were enrolled in clinical trials registered as ChiCTR1800017051.

• Authors: Huan Zhang, Man Liu, Xia Xiao, Hairong Lv, Yanyu Jiang, Xin Li, Ting Yuan, Mingfeng Zhao
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 63 Issue 6 Pg. 1418-1427 (06 2022) ISSN: 1029-2403 [Electronic] United States
• PMID: 35105265 (Publication Type: Journal Article)

Chemical References

• B-Cell Maturation Antigen
• Receptors, Chimeric Antigen

Topics

• Animals
• B-Cell Maturation Antigen (agonists)
• Cell- and Tissue-Based Therapy
• Clinical Trials as Topic
• Combined Modality Therapy (adverse effects)
• Humans
• Immunotherapy, Adoptive
• Mice
• Middle Aged
• Multiple Myeloma (drug therapy)
• Receptors, Chimeric Antigen (therapeutic use)